Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accumulated Depreciation: 2020-2023

  • Relay Therapeutics' Accumulated Depreciation rose 28.24% to $23.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $23.6 million, marking a year-over-year increase of 28.24%. This contributed to the annual value of $23.6 million for FY2023, which is 28.24% up from last year.
  • As of Q4 2023, Relay Therapeutics' Accumulated Depreciation stood at $23.6 million, which was up 28.24% from $18.4 million recorded in Q4 2022.
  • Relay Therapeutics' Accumulated Depreciation's 5-year high stood at $23.6 million during Q4 2023, with a 5-year trough of $10.5 million in Q4 2020.
  • For the 3-year period, Relay Therapeutics' Accumulated Depreciation averaged around $18.8 million, with its median value being $18.4 million (2022).
  • Data for Relay Therapeutics' Accumulated Depreciation shows a peak YoY spiked of 36.44% (in 2021) over the last 5 years.
  • Relay Therapeutics' Accumulated Depreciation (Quarterly) stood at $10.5 million in 2020, then soared by 36.44% to $14.4 million in 2021, then increased by 27.99% to $18.4 million in 2022, then increased by 28.24% to $23.6 million in 2023.
  • Its last three reported values are $23.6 million in Q4 2023, $18.4 million for Q4 2022, and $14.4 million during Q4 2021.